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The impact of pollen exposure on population allergic illness is poorly characterized. We explore the association of tree pollen and
over-the-counter daily allergy medication sales in the New York City metropolitan area. Dates of peak tree pollen (maple, oak, and
birch) concentrations were identified from 2003 to 2008. Daily allergy medication sales reported to the city health department were
analyzed as a function of the same-day and lagged tree pollen peak indicators, adjusting for season, year, temperature, and day of
week. Significant associations were found between tree pollen peaks and allergy medication sales, with the strongest association at
2-day lag (excess sales of 28.7% (95% CI: 17.4–41.2) over the average sales during the study period). The cumulative effect over the
7-day period on and after the tree pollen peak dates was estimated to be 141.1% (95% CI: 79.4–224.1). In conclusion, tree pollen
concentration peaks were followed by large increases in over-the-counter allergy medication sales.
1. Introduction
Increased concentrations of various pollens have been associ-
ated with higher rates of allergic sensitization [1, 2], tendency
towards increased asthma episodes [3], higher numbers of
asthma-related emergency department (ED) visits [4–7] and
hospital admissions [8, 9], as well as higher numbers of
allergic rhinitis ED visits [10] and physician visits [11].
Allergic rhinitis, a type of allergic airway disease that is a
risk factor for increased asthma severity [12], decreases the
quality of life of a substantial proportion of the United States
population (10%–30% of adults and up to 40% of children)
and imposes large costs on our health care system [13]. The
direct costs for allergic rhinitis alone, including both health
services and prescription medication sales, were $11.2 billion
in 2005 [14]. Over-the-counter (OTC) allergy medication
sales account for an increasing additional cost associated with
allergic rhinitis [15, 16].
Allergy medication use is also believed to be associated
with higher pollen concentrations although only one prior
study was found looking specifically at this outcome [17],
a French study that looked at prescription medications.
In addition, there is variability in pollen types examined,
demographics, temporal covariates, and health outcomes,
with some studies suggesting interactions of pollen exposure
with air pollution or personal characteristics [18]. Not all
studies have shown positive associations between pollen
and respiratory illness [19], and results have varied by
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pollen species [20]. Furthermore, lagged effects have not
been consistently examined. Finally, there are no established
systems for surveillance of pollen-related allergic illness over
time. Thus, the temporal relationship between pollen peaks
and fluctuations in morbidity due to allergic diseases is not
well-characterized.
Allergic airway disease primarily involves ambulatory
care and symptomatic relief via self-administration of med-
ications. Thus, studies that look at severe health outcomes
such as ED visits and hospitalizations for respiratory illness
only capture a small fraction of the population affected.
However, records of more severe outcomes are more widely
available and historically reliable.
This study attempts to broaden the understanding of
the association of pollen and population health behaviors
by analyzing whether peaks in tree pollen concentration are
associated with peaks in OTC allergy medication sales over
a six-year period in New York City (NYC). By using a new
method of minor illness surveillance, this data has the ability
to capture an association of pollen with a more proximal
indicator of allergic disease and thus possibly a larger fraction
of the illness burden.
2. Methods
2.1. Data
2.1.1. Pollen Data. Airborne pollen was collected with a
Burkard volumetric spore trap (Burkard Manufacturing Co.,
Rickmansworth, UK)—Hirst-type sampler [21]—located on
the rooftop at Fordham University’s Louis Calder Biological
Station in Armonk, NY about 30 miles north of Manhattan.
This station is the closest long-term pollen record for the
NYC region. Trained counters carried out microscopic anal-
ysis of pollen. Resulting daily pollen counts were converted
into concentrations (particles per cubic meter of air) for
the six years from 2003 to 2008. Peak dates for each pollen
type in each year were identified. We focused on reviewing
archival pollen slides from dates near expected seasonal
peaks to identify the actual peak dates. We used peak
pollen dates rather than daily pollen counts as the exposure
metric, because peak dates are easily identified and are not
affected by differential measurement methods and pollen
counters. Thus, peak dates are more generalizable across
different settings, and this analysis provides conservative
estimates of the impact of pollen on allergy medication
sales. Additionally, we were able to identify peaks without
a completely continuous data set which will be the focus of
future analyses.
For this study, we analyzed daily concentrations of four
genera of tree pollen: elm (Ulmus spp.), maple (Acer spp.),
birch (Betula spp.), and oak (Quercus spp.). These subtypes
were selected a priori, because they are clinically relevant
aeroallergens in the U.S. [22] and have well-established
sensitization patterns in populations from the northeast
region of the U.S. [23, 24]. Other important pollens,
including weed pollens such as ragweed and Artemesia sp.
(sage/mugwort/wormwood) as well as grass pollens were
excluded from the study in order to focus on earlyseason
allergy. We defined “early-season” as March through May to
capture the tree pollen peaks that are well known among
allergists (per clinical pollen season charts) to occur in the
northeastern U.S. during these months.
2.1.2. Weather and Air Pollution Data. Daily meteorological
data from LaGuardia International airport in New York
was downloaded from the National Climatic Data Center.
Daily average temperature was selected based on a review
of previous literature. While preseason temperature and
precipitation are positively correlated with tree pollen con-
centration [22], our study looks at short-term impact only.
Data for particulate matter with aerodynamic diameters
less than 2.5 microns (PM2.5) were obtained from U.S.EPA
Air Quality System for NYC’s five boroughs (21 sites).
The temporal variations of PM2.5 across these monitors
were highly correlated (r > 0.85). Therefore, we computed
the average of multiple sites, taking into consideration the
difference in site-specific means and standard deviations
[25].
2.1.3. Allergy Medication Sales Data. Data on OTC pharmacy
sales are reported electronically to the NYC Department of
Health and Mental Hygiene on a daily basis from over 200
store locations, disproportionately in Manhattan but also
from the other four NYC boroughs (Table 1) and nearby
suburbs in New York State and New Jersey. The store
locations in this database cover approximately 30% of retail
pharmacies in NYC [26].
Although initially collected primarily for communicable
disease surveillance, the data has served other purposes such
as smoking cessation intervention evaluation [27]. For this
analysis, the following brand-name and generic products
were classified as allergy medications: Alavert, Benadryl,
Claritin, loratidine, Sudafed, and Tavist, as well as other oral
and nasal spray medications that include the word “allergy”
in their name.
2.2. Data Analysis. Our main interest was the alignment
(i.e., the timing and lag structure) of the tree pollen
peaks and major peaks in the allergy medication sales.
Since the absolute magnitude of the pollen peaks can vary
geographically within NYC, and because we used pollen data
from a single station outside the city, absolute peak values
from this database may not accurately reflect the pollen
exposures of the entire city’s residents. Therefore, we used
an indicator variable (1 for peak dates; 0 otherwise) for
the tree pollen peak dates, rather than the absolute pollen
concentration. We defined “tree pollen peak date” to be the
date with the highest pollen concentration from available
data during the March through May period each year for
each genus. There were two peak dates for elm in 2007 and
2008 because there were two dates with the same pollen
concentration in each of those years. For the other species,
there was only one peak date in each year. Thus, we had a
total of 26 pollen peak dates over the six-year study period.
However, 18 tree pollen peak dates were included in the
analysis because elm was excluded due to no corresponding
major short-term peaks in allergy medication sales.
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Table 1: Distribution of daily allergy medication sales, temperature, and fine particles (PM2.5), March–May, 2003–2008.
Percentile 5th 25th 50th 75th 95th
Allergy medication sales (units)
All boroughs 1792 2594 3302 4903 7984
Manhattan 1151 1798 2314 3383 5554
Bronx 51 66 86 130 270
Brooklyn 176 229 294 435 814
Queens 184 230 308 464 844
Staten Island 36 51 68 88 138
Outside NYC 125 159 208 300 491
Environmental variables
Temperature (Degrees F) 34 44 53 59 70
Fine particles (ug/m3) 4 6 10 15 25
We developed a regression model to estimate the impact
of the 18 tree pollen peak dates on the daily allergy med-
ication sales, adjusting for potential confounding factors.
Since we expected delayed effects and multiday effects, we
examined lags 0 through 6 days from the pollen peak
dates (i.e., we compared today’s allergy medication sales
with today’s tree pollen peak, with yesterday’s pollen peak,
etc.). To test consistency with a causal relationship, we also
examined the “wrong side” of the lag up to 6 days (i.e., we
compared today’s allergy medication sales with tomorrow’s
pollen peak, with the day after tomorrow’s pollen peak, etc.).
We first included individual lags of the tree pollen peak date
indicator to determine the lag structure of associations, and
then included all seven day lags to estimate the multiday
effects (i.e., unconstrained distributed lag model).
We included the following five temporal covariates in
the regression model: a day-of-week indicator variable as
a factor variable to fit the weekly sales pattern (i.e., fewer
sales on weekends), a year indicator variable to account for
year-to-year variability in the medication sales, and three
temperature variables to capture the effects of temperature
on allergy symptoms [28] or on purchasing behaviors. Since
we do not know the functional form of the relationship,
we fitted a smooth function of temperature using natural
cubic splines with three degrees of freedom to allow a U-
shaped relationship. Likewise, we included the average of
1- through 3- day lagged temperature to model the delayed
effect, with natural cubic splines with three degrees of
freedom. Since there are general upward and downward
trends in allergy medication sales within the March through
May period that may not be associated with pollen, we
included a smooth function of study days using natural cubic
splines with 8 degrees of freedom within each season. We
chose 8 degrees of freedom based on penalized splines that
determine the optimum effective degrees of freedom [29]
given no explanatory variables to force the shape of the trend.
However, since the seasonal trend in allergy medication sales
within our study period may also reflect the actual effect of
pollen, our main model conservatively estimates the impact
of pollen. Therefore, we conducted sensitivity analysis using
natural cubic splines with 6, 4, and 2 degrees of freedom.
We conducted further sensitivity analysis on models without
adjustment for seasonal trend, year-to-year variation, and
temperature. Finally, pollen peak dates may coincide with
days when air is stagnant, and therefore air pollution is high.
In order to address possible confounding, we also analyzed
the city-wide average fine particle (PM2.5) concentration at
lag 0 through 6 days using the same main model we used to
estimate the impact of pollen. The effect of pollen was also
estimated with PM2.5 in the model.
To assess potential geographic differences in the impact
of pollen on allergy medication sales, we also applied the
main model described above separately to each of the five
boroughs and the area outside of NYC.
Daily allergy medication sales exhibited a highly skewed
distribution. We, therefore, conducted the analysis described
above with log-transformed outcome data. The extent of
the impact was expressed as percent excess from the average
allergy medication sales as measured by number of units
sold during March through May during the study years,
adjusting for the covariates described above. Analysis was
conducted using statistical software R version 2.10 (R Core
Development Team, 2009).
3. Results
Figure 1 shows time-series plots of OTC allergy medication
sales for the entire city from 2003 to 2008, with tree pollen
peak dates superimposed. While there is a general upward
trend in allergy medication sales each spring before the
pollen peak dates, the pollen peak dates do appear to coincide
with sharp peaks in the medication sales. The increase in sales
can partially be explained by the changes in number of stores
reporting, which increased from 206 in 2003 to 231 in 2008.
Table 1 shows the data distribution of allergy medication
sales by borough, temperature, and PM2.5 concentration.
The temporal pattern of allergy medication sales were highly
correlated across boroughs.
Figure 2 shows the estimated impacts of tree pollen peaks
on percentage change in allergy medication sales at specific
lags. Significant associations were found at lags 1 through
3 days. No significant association was found on the “wrong
side” of lagged associations (i.e., with allergy medication sales




























Figure 1: Time-series plot of daily allergy medication sales.
Superimposed lines are dates of tree pollen peaks color coded by
genera.
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Figure 2: Estimated impacts of the tree pollen peaks on the
percentage change in the mean allergy medication sales during
March through May of the study period. Each individual lagged
peak indicator variable was included separately in the model.
Figure 3 shows the estimated impacts of tree pollen
peaks when all lagged peak date indicators were included
simultaneously. The largest statistically significant impact
occurred at 2-day lag (28.7% [95% CI: 17.4, 41.2]), followed
by lag 1 day. In the distributed lag model, the sum of the
effects over the seven-day period was 141.1% (95% CI: 79.4,
224.1). Table 2 shows numerical results for all the lagged
pollen peak indicator variables from our main model (shown
in Figure 3) which is fully adjusted, as well as results sorted
by subarea, results from sensitivity analysis, and estimated
percent excess risk for PM2.5. The estimated pollen impacts
were highest in the Bronx and lowest in Staten Island but




























Figure 3: Estimated impacts of the tree pollen peaks on the
percentage change in the mean allergy medication sales during
March through May during the study period. All the lagged peak
indicators were included in the model.
were generally comparable across boroughs. Adjusting for
PM2.5 slightly decreased risk estimates for pollen, but PM2.5
itself was not associated with allergy medication sales at any
of the lags examined (see the last row of Table 2). PM2.5 levels
were comparable between pollen-peak days and non-peak
days (Figure 4). Not adjusting for year to year variation only
slightly changed the pollen impact estimates. Not adjusting
for temperature moderately increased the estimated pollen
impact. This finding may in part be explained by the fact
that pollen peak dates tend to occur in the warmer part
of the March through May period (Figure 4). Removal of
the seasonal trend term or less aggressive adjustment for
the seasonal trend (i.e., using 2 or 4 degrees of freedom)
substantially increased the pollen impact estimates. Most
importantly, these alternative models showed essentially the
same lag structure of associations.
4. Discussion
We found that OTC allergy medication sales increased
significantly on the day of a pollen peak for maple, oak or
birch, and that the increase persisted for 3 days after the
peak. The maximum single-day increase in sales—∼29%—
occurred 2 days after a tree pollen peak. The multiday effect
over one week was estimated to be 141%. Our findings
indicate that monitoring OTC medication sales may be a
useful method of population surveillance for allergic illness
and the impact of pollen, as well as a potential measure of
consumer anticipation of pollen events in response to public
health advisories or other messaging.
Our findings are generally consistent with other studies
examining the relation of ambient pollen to minor allergic
illness. In an urban area in France, a study found that daily
purchases of prescription allergy medications were associated
with same-day concentrations of grass pollen and some tree
pollens while controlling for weather and air pollution [17].
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Table 2: Estimated percent excess allergy medication sales at lags 0 through 6 days from pollen peak dates and PM2.5 (last row).













































































































































































































































A study in Ottawa, Canada, found no effect of tree pollen
on ED visits for conjunctivitis and rhinitis, but ragweed and
fungal spore concentrations appeared to be associated with
same day ED visits while controlling for weather and air
pollution. The exploration of lagged effects was not described
in detail by the authors [10]. In Toronto, Canada, physician
visits among the elderly for allergic rhinitis were associated
with 10-day average ragweed concentrations but not with air
pollution [11]. One strength of our study is that it includes a
fuller examination of lags than these previous studies.
The estimated effects of pollen on allergy medication
sales were sensitive to adjustment for the seasonal trend
within the March through May period. Using 8 degrees of
freedom to fit the broad trend in the allergy medication sales
may overcontrol for season, therefore underestimating the
impact of tree pollen. Broad increases in medication sales
occurred around the dates of pollen peaks. Much of the
broad increase is likely explained by our seasonal covariate
rather than our intermittent pollen peak indicator. Another
limitation of our model is that it is possible that some
individuals respond to pollen with a longer delay than seven
days. It is also likely that pollen concentrations lower than
the peak day concentration also cause allergic symptoms that
contribute to medication sales. Furthermore, the model does
not account for the impacts of re-entrainment/resuspension
of pollen particles and ongoing pollen production from other
sources that may persist for days without producing distinct
peaks and yet affecting the population. This study focused
on determining the temporal relationship between the sharp
peaks in tree pollen and allergy medication sales rather the
total impact of pollen over the season.
As far as we are aware, our study is the first to use OTC
allergy medication sales directly reported from pharmacies
as an indicator of allergic illness. An advantage of this
approach is that this health data reflects minor illness, as
many will not seek health care nor have claims filed for
prescription medications. The observed associations support
use of genus-specific tree pollen season charts in clinical
6 ISRN Allergy

































Figure 4: PM2.5 levels and temperature by nonpeak days versus peak days of pollen.
allergy practice, which are not currently being used in allergy
clinics in New York (personal correspondence, President of
the NY Allergy Society, January 2010).
Limitations of this approach include the possibility that
individuals may self-medicate using previously purchased
OTC medications, that the single purchase of OTC allergy
medication could result in usage at multiple times other than
the day of purchase, and that available in-home medications
may vary within a calendar year. Thus, our analysis likely
underestimates the overall contribution of pollen to use
of OTC allergy medications. Furthermore, purchase of an
OTC allergy medication does not describe frequency of use,
severity of symptoms, nor the number of individuals using
a particular medication. Additionally, no demographic data
about those purchasing the allergy medications is available.
Conclusions about the observed increase in total allergy
medication sales over the study period representing an
increase in morbidity might be premature as the trend
could also be the result of medications formerly requiring
a prescription being sold as OTC products and therefore
reflect the public response to increased advertising of these
products.
Work is needed on the specific magnitude of health
impacts of aeroallergens, such as attributable burden of
disease not only to allergic rhinitis but also to asthma,
subpopulation sensitivity, better understanding of pollen
type sensitivities, and rate of progression of pollen-induced
symptoms to more severe health events. In addition, efforts
to better detail the role of weather and climate variables
as effect modifiers in pollen-related health impacts, the
geospatial variation of pollen concentrations, and the timing
and intensity of the pollen season will contribute to work in
this field. Future work should explore relationships between
meteorologic, variables and pollen using continuous daily
concentration data and not just peak measures.
5. Conclusions
Findings from this study suggest that peaks in maple,
oak, and birch pollen concentrations may have prognostic
value in anticipating acute allergic responses in the study
region. Early warning of spring pollen peaks based on
ongoing surveillance and meteorological forecast models
could potentially inform clinical practice and reduce mor-
bidity. The importance of this work lies not only in its
potential contribution to public health surveillance and
clinical guidance but also in its ability to inform projections
of future pollen-related morbidity under a changing climate.
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